Skip to main content

Articles

Page 38 of 38

  1. Alzheimer's disease is a progressive neurodegenerative disorder with high prevalence in old age. It is the most common cause of dementia, with a risk reaching 50% after the age of 85 years, and with the increa...

    Authors: Dimitrios Avramopoulos
    Citation: Genome Medicine 2009 1:34
  2. Functional genomic studies are dominated by transcriptomic approaches, in part reflecting the vast amount of information that can be obtained, the ability to amplify mRNA and the availability of commercially s...

    Authors: Julian L Griffin and Christine Des Rosiers
    Citation: Genome Medicine 2009 1:32
  3. Despite the recent success of genome-wide association studies (GWASs) in identifying loci consistently associated with coronary artery disease (CAD), a large proportion of the genetic components of CAD and its...

    Authors: Matthew B Lanktree and Robert A Hegele
    Citation: Genome Medicine 2009 1:28
  4. Disparities in health outcomes of members of different ancestral or ethnic groups can be observed in both developed and developing countries and continue to be a global concern. Genomic medicine can help towar...

    Authors: David Gurwitz and Jeantine E Lunshof
    Citation: Genome Medicine 2009 1:24
  5. The wide general publication of a putative genetic test for athletic supremacy is clearly an abuse of genetics and reveals an undercurrent of hucksterism in biomedical science.

    Authors: David G Nathan and Stuart H Orkin
    Citation: Genome Medicine 2009 1:18
  6. The availability of personalized genomic tests, ordered directly by consumers, is rapidly growing. These tests are unlike other genetic or biochemical tests in the sheer amount of data they provide, but interp...

    Authors: David Magnus, Mildred K Cho and Robert Cook-Deegan
    Citation: Genome Medicine 2009 1:17
  7. The genome era in medicine is upon us. Questions that arise from patient and family care are a watershed for research and technology, which in turn fuel the cycle of opportunity for impact through delivery of ...

    Authors: Janet A Buchanan, Andrew R Carson, David Chitayat, David Malkin, M Stephen Meyn, Peter N Ray, Cheryl Shuman, Rosanna Weksberg and Stephen W Scherer
    Citation: Genome Medicine 2009 1:16
  8. The Human Gene Mutation Database (HGMD®) is a comprehensive core collection of germline mutations in nuclear genes that underlie or are associated with human inherited disease. Here, we summarize the history of t...

    Authors: Peter D Stenson, Matthew Mort, Edward V Ball, Katy Howells, Andrew D Phillips, Nick ST Thomas and David N Cooper
    Citation: Genome Medicine 2009 1:13
  9. It has been established that heterozygous carriers of ataxia-telangiectasia-causing mutations in the ATM gene are at approximately two-fold higher risk of breast cancer. Several studies have attempted to assess t...

    Authors: Roger L Milne
    Citation: Genome Medicine 2009 1:12
  10. Genome medicine uses genomic information in the diagnosis of disease and in prescribing treatment. This transdisciplinary field brings together knowledge on the relationships between genetics, pathophysiology ...

    Authors: Aislyn D Wist, Seth I Berger and Ravi Iyengar
    Citation: Genome Medicine 2009 1:11
  11. The use of race in biomedical research has, for decades, been a source of social controversy. However, recent events, such as the adoption of racially targeted pharmaceuticals, have raised the profile of the r...

    Authors: Timothy Caulfield, Stephanie M Fullerton, Sarah E Ali-Khan, Laura Arbour, Esteban G Burchard, Richard S Cooper, Billie-Jo Hardy, Simrat Harry, Robyn Hyde-Lay, Jonathan Kahn, Rick Kittles, Barbara A Koenig, Sandra SJ Lee, Michael Malinowski, Vardit Ravitsky, Pamela Sankar…
    Citation: Genome Medicine 2009 1:8
  12. The Genetic Information Nondiscrimination Act of 2008 (GINA) was recently enacted in the United States. Its supporters have applauded the passage of GINA, and they hope that it will alleviate public fear about...

    Authors: Amy L McGuire and Mary Anderlik Majumder
    Citation: Genome Medicine 2009 1:6

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 10.4
    5-year Journal Impact Factor: 12.6
    Source Normalized Impact per Paper (SNIP): 2.375
    SCImago Journal Rank (SJR): 4.975

    Speed 2023
    Submission to first editorial decision (median days): 9
    Submission to acceptance (median days): 185

    Usage 2023
    Downloads: 2,331,772
    Altmetric mentions: 4,916

  • Peer Review Taxonomy

    This journal is participating in a pilot of NISO/STM's Working Group on Peer Review Taxonomy, to identify and standardize definitions and terminology in peer review practices in order to make the peer review process for articles and journals more transparent. Further information on the pilot is available here

    The following summary describes the peer review process for this journal:

    • Identity transparency: Single anonymized
    • Reviewer interacts with: Editor
    • Review information published: None

    We welcome your feedback on this Peer Review Taxonomy Pilot. Please can you take the time to complete this short survey.